TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05116345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXTENZA
Description: Intracanalicular Dexamethasone ophthalmic insert (0.4mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Dexamethasone
Description: topical dexamethasone drops
Study: NCT06083714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization Exercises
Description: Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
Study: NCT06021613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Randomized instructions
Description: Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.
Study: NCT06570174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral protein supplements
Description: Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
Study: NCT06557811

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
Study: NCT06475300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05860244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Syrup for 6 months
Study: NCT06564688

Intervention type: DIAGNOSTIC_TEST
Intervention: Swallowing function test
Description: The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Swallowing function test
Description: The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Swallowing function test
Description: The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants.
Study: NCT05724771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)
Description: OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
Study: NCT06563687

Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom ONE+
Description: In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom ONE+
Description: In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
Study: NCT05866640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2 filter and delivery system
Description: Placement of F2 device in aorta to cover great cerebral vessels
Study: NCT05177380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation program of facial involvement in systemic sclerosis
Description: Personalized rehabilitation program of facial involvement in systemic sclerosis

Intervention type: OTHER
Group type: OTHER
Intervention: Delivery of a standard prescription for facial rehabilitation
Description: Delivery of a standard prescription for facial rehabilitation
Study: NCT04831229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform activities on interactive tablet
Description: AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform activities on interactive tablet
Description: AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform passive on interactive tablet
Description: The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform passive on interactive tablet
Description: The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions.
Study: NCT05501899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
Study: NCT06083714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercises
Description: It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Schroth Exercises
Description: It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
Study: NCT05904262

Intervention type: OTHER
Intervention: Foot Sole Sensation Evaluation
Description: Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
Study: NCT06148662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention (negative control)
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water (positive control)
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental foam Biorepair PERIBIOMA
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental foam WATER:DENT
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental spray BUCCOTHERM
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.
Study: NCT05272280

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External oblique intercostal (EOI) block
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
Study: NCT05542199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss program
Description: Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral weight loss program
Description: Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
Study: NCT05978778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wii sports game
Description: wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-hand writing skills
Description: pre-hand writing skills

Intervention type: OTHER
Group type: OTHER
Intervention: pre-hand writing skills
Description: pre-hand writing skills
Study: NCT06692933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg oral clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg oral clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg oral clopidogrel
Study: NCT06692270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W, D1 ; 2 cycles
Study: NCT06692647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4318
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Oral administration
Study: NCT06692816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation
Description: As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
Study: NCT06692842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONEMO App
Description: The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
Study: NCT05543889

Intervention type: OTHER
Intervention: Educational package
Description: Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
Study: NCT06734325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Oral Health Intervention
Description: 46 messages delivered over a 3-month period (12 weeks) via WhatsApp
Study: NCT06737627

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06737484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APPLYING TOPICAL OLIVE OIL
Description: 1. Preparation phase: Before the application, hand hygiene will be provided, materials will be prepared, and the application will be carried out wearing gloves. The patient bed will be prepared, a stretcher cover and a bed protector will be laid. A screen will be used for patient privacy and only the areas to be applied will be opened in order. Itchy areas will be identified. Before starting the application, olive oil will be tested by applying it to a small area on the inside of the patient's arm in case of any allergic reaction.~2. Application of olive oil: 3 drops of olive oil will be dropped on the itchy areas (excluding the scalp and private areas) for every 25 cm square area and gently spread over the area for 30-60 seconds. Since there is a 5-7 minute absorption period from the skin, the area will be kept open and then a VAS score will be taken.~3. After the application: The procedure will be marked on the patient follow-up form.
Study: NCT06743074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot exercise
Description: foot exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hip exercise
Description: hip exercise

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: control
Study: NCT06748014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aescin in Horse Chestnut
Description: Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPFF
Description: MPFF 3000 mg 7 day then 1000 mg 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPFF
Description: MPFF 3000 mg 7 day then 1000 mg 2 months
Study: NCT06747013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Ablation Catheter
Description: a point ablation catheter using a pulse field energy
Study: NCT06747728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
Study: NCT06746870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2510
Description: Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2510
Description: Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2510
Description: Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (pemetrexed + cisplatin/carboplatin)
Description: Non-squamous non-small cell lung cancer (NQ-NSCLC): Pemetrexed 500 mg/m2 in combination with carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles, followed by maintenance treatment with pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (paclitaxel + cisplatin/carboplatin)
Description: Squamous non-small cell lung cancer (SQ-NSCLC): Paclitaxel 175 mg/m2 + carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy(Nab-paclitaxel)
Description: Nab-paclitaxel, 100 mg/m2, 4 weeks as a cycle, administered on D1, 8, and 15 of each cycle.
Study: NCT06746727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE)
Description: This single-arm intervention will pilot a new, manualized intervention adapted from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use. ACT for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) aims to assist Veterans in developing skills central to psychological flexibility (e.g., acceptance, mindfulness, commitment to values-based action) to improve their relationship functioning and decrease IPV use in the presence of PTSD symptoms (e.g., anger, irritability, detachment from others) and alcohol use issues (e.g., cravings, triggers, disconnection from valued roles).
Study: NCT06747182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile phone-based intervention
Description: Participants in intervention group will receive a 12-week mobile phone-based intervention with follow-up at week 26.
Study: NCT06746844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViewMind Atlas™
Description: The intervention involves the use of ViewMind Atlas™, a novel digital tool for cognitive assessment, and traditional cognitive tests. The ViewMind Atlas™ device evaluates cognitive performance through eye-tracking technology and advanced analytics, providing objective measurements of cognitive function. Traditional cognitive tests are used as the standard comparator to validate the device's diagnostic performance
Study: NCT06745999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ameluz 10% Topical Gel
Description: Paired with device intervention of red light PDT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ameluz 10% Topical Gel
Description: Paired with device intervention of red light PDT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light PDT
Description: Paired with drug intervention of Ameluz 10% topical gel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light PDT
Description: Paired with drug intervention of Ameluz 10% topical gel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid Nitrogen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid Nitrogen
Study: NCT06746649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined training
Description: 12-week long time specific combined training 2 times a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined training
Description: 12-week long time specific combined training 2 times a week
Study: NCT06747832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNK cells
Description: Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.